5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Morepen Laboratories Ltd.

•
morepen.comBSE: 500288NSE: MOREPENLAB
Market Cap₹ 6,354 Cr.
Current Price
High / Low₹ 123 / 33
Stock P/E45.2
Book Value₹ 24
Price to Book1.49
Dividend Yield0.17 %
ROCE10.2 %
ROE8.0 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 394.0% YoY, showing strong momentum
  • Company has consistently been profitable over the last 5 years
  • Company comfortably covers its interest (8.3x coverage)
  • Company maintains a comfortable, low leverage position

CONS

  • Promoter holding has decreased over last 2 years: -2.6pp
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.44x)
  • Free cash flow has been persistently negative
  • Total debt has risen sharply - up 145.2% year on year
  • Valuation is stretched - P/E of 45.2 is well above its own 5-year median (22.2)
  • Company has delivered a poor profit growth of -0.3% over past five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.MOREPENLAB115.9545.216353.520.1756.35393.96570.1334.0710.1914.48
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
401422445423455438453466425412484485570
375388394375404394417424401381438460501
Operating Profit26345148524436422431462469
OPM %6.51%7.96%11.37%11.44%11.34%10.07%7.98%9.07%5.68%7.46%9.57%5.04%12.16%
23443555430485
Interest0021111544445
Depreciation88810625169111068
Profit before Tax21294442484635261646352375
Tax %28.67%25.91%27.33%31.90%24.91%24.27%24.20%21.00%26.48%10.18%22.39%32.59%24.40%
Net Profit0000363527201141281656
0.290.420.630.540.710.650.490.350.200.750.500.281.03

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
5956077698531,1881,5471,4181,6901,8121,8061,951
5345427017851,0701,4101,3381,5321,6381,6801,780
Operating Profit6165686911913780159174126171
OPM %10.31%10.67%8.79%8.03%9.98%8.84%5.61%9.38%9.61%6.96%8.76%
44491220614184748
Interest8422222481617
Depreciation3434403730282833293636
Profit before Tax243029399912756135155120179
Tax %0.00%0.00%1.15%14.14%1.44%19.75%30.63%28.65%23.91%20.24%21.43%
Net Profit2430293497102399711896141
EPS0.530.660.640.752.151.960.771.882.151.73—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%9.29%11.55%—

COMPOUNDED SALES GROWTH

10 Years:
14%
5 Years:
9%
3 Years:
8%

COMPOUNDED PROFIT GROWTH

10 Years:
22%
5 Years:
0%
3 Years:
35%

STOCK PRICE CAGR

10 Years:
17%
5 Years:
16%
3 Years:
48%
1 Year:
114%

RETURN ON EQUITY

10 Years:
14%
5 Years:
12%
3 Years:
11%
Last Year:
8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Sep 18

₹ 0.10

Rs.0.2000 per share(10%)Final Dividend

2026

Aug 4

₹ 0.10

Rs.0.2000 per share(10%)Final Dividend

2025

May 12

₹ 0.10

Rs.0.2000 per share(10%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital909090909096102102110110
Minority Interest-1-0-0-0-0-0-00311
1061361631942914576517451,0471,137
17113714172122293190178
Trade Payables125175168172209258227295363317
4648180190248238102120138194
Total Liabilities5385866156638581,0701,1101,2931,7781,936
272264236216225252267307489513
Capital Work in Progress000021417242822
0001100185124
657794138175276229249300272
0000000325325333
Cash & Bank863239684656524969
194238253269387482541334502604
Total Assets5385866156638581,0701,1101,2931,7781,936

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
4163181752-35-75733233
Cash from Investing-14-27-13-12-70-32-47-83-322-123
Cash from Financing-24-38-054766144530097
3-14428-266-5107

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
38.2235.6535.6535.6535.6535.6535.6535.6535.65
1.672.082.221.941.721.621.621.581.46
2.141.691.641.671.501.491.251.251.28
0.010.010.010.010.010.010.010.010.01
57.9660.5660.4760.7261.1161.2161.4661.5061.59

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-07
General Updates

2026-09-07 - Business Update First Phase of Manufacturing Capacity Expansion Completed Ahead of Schedule

2026-09-03
Copy of Newspaper Publication

2026-09-03 - Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26

2026-09-02
Updates

2026-09-02 - Morepen Laboratories Limited has informed the Exchange regarding 'Morepen Laboratories Limited has informed the Exchange regarding 'Letter To Members, (No E-Mail Id Registered), Comprising Weblink Of The Annual Report : 2025-26'.'.

2026-09-02
Shareholders meeting

2026-09-02 - Morepen Laboratories Limited has informed the Exchange about Shareholders meeting

2026-08-26
Copy of Newspaper Publication

2026-08-26 - Newspaper publication-information relating to 41st Annual General Meeting, Dividend and Record Date

2026-08-06
General Updates

2026-08-06 - Morepen Laboratories Limited has informed the Exchange about allotment of equity shares by Morepen RX Limited, wholly owned subsidiary, to the company

2026-08-05
Copy of Newspaper Publication

2026-08-05 - Morepen Laboratories Limited has informed the Exchange about Newspaper Publication - Financial Results for the quarter ended June 30, 2026

2026-08-04
Monitoring Agency Report

2026-08-04 - Monitoring agency report for the quarter ended June 30, 2026

2026-08-04
General Updates

2026-08-04 - Morepen Laboratories Limited has informed the Exchange about Intimation of 41st Annual General Meeting scheduled to be held on September 26, 2026

News

Recent coverage and analyst commentary for MOREPENLAB

Loading news…

🤖

AI Stock Analyst

Morepen Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login